HIV / AIDS
HIV / AIDS
HIV infection destroys CD4+ T cells. AIDS: CD4 <200 or AIDS-defining illness. ART (antiretroviral therapy) achieves viral suppression. U=U: Undetectable = Untransmittable. PrEP prevents HIV acquisition.
Latest evidence
Candida Esophagitis in Patients with Solid Organ Cancers.
Challenges in achieving the UNAIDS 95-95-95 targets: evaluation of the antiretroviral therapy program among adult HIV/AIDS patients at Woldia General Hospital, Northeast Ethiopia.
Anemia, iron, and HIV: decoding the interconnected pathways: A review.
Predictors of the observed high prevalence of loss to follow-up in ART-experienced adult PLHIV: a retrospective longitudinal cohort study in the Tanga Region, Tanzania.
What this condition is
What are HIV and AIDS?HIV stands for human immunodeficiency virus. It harms your immune system by destroying a type of white blood cell that helps your body fight infection.AIDS is the final stage of infection with HIV. It happens when the body's immune system is badly damaged because of the virus. Not everyone with HIV develops AIDS.Are there treatments for HIV?There is no cure for HIV, but there are many medicines…
Open official source →Terms and documentation support
Condition matches & synonyms
TermsRelated diagnostic names, synonyms, and documentation wording that may appear in clinical references and charting.
ICD-10 quick links
CodesFor study support, terminology recognition, and documentation language.
Tests performed
Recognize the drug and the class
NANDA diagnoses & care plans
Use these direct links to open nursing diagnoses and care-plan support related to HIV / AIDS.
Additional official research
Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium
This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes. Primary outcome • Evaluate patient perception of, and satisfaction with, long…
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
This study will assess how effective, safe, and long-lasting a long-acting antiretroviral therapy (ART) using CAB LA + RPV LA is for people with HIV who still have detectable virus levels despite being on oral ART. The study will also cons…
Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study
This study evaluates the real-world effectiveness and safety of a long-acting injectable HIV treatment consisting of cabotegravir and rilpivirine in people living with HIV-1. The focus is on individuals with HIV-1 subtype A6, which is comm…
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
This is an open-label, dose-escalation study to investigate the safety, tolerability and pharmacokinetics (PK) of single subcutaneous (SC) administration of long acting (LA) Cabotegravir (CAB) 200 milligrams per milliliter (mg/mL) with Rec…
Kuwa Free! - Live Free!
The study investigators are conducting foundational pharmacokinetic (PK) and qualitative studies, among 15-24 years old (inclusive) adolescent girls and young women living with HIV (AGYWLHIV) already on oral antiretroviral therapy (ART) an…
Plain-language study support
Useful for plain-language reinforcement and quick review.